Many of the problems in the mpox response were due to a deflated and exhausted public health workforce across the country.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
No transmission was noted in encampments, despite potential sharing of sleeping bags, clothes, and utensils.
Since the WHO's last update on March 30, countries have reported 206 new cases and 4 deaths, with all the new deaths in the Americas.
Overall, between May and December of 2022, mpox incidence in Black and Hispanic males was higher than in their White counterparts.
Only 17.1% of the US population live within 15 minutes of a vaccination site, and 50% live more than an hour away.
The proportion of cases in vaccinated patients was much higher than the previous 4 months.
In other mpox developments today, the WHO in an update said cases continue to decline, though Japan reported some localized spread.
The Americas reported the vast majority of new cases over the past 3 weeks—408 of 442.
Of the 85 videos analyzed, only 33% covered all content items that were highlighted in clinical practice guidelines.
Estimated 1-dose protection against symptomatic mpox was 78% after at least 14 days, ranging from 71% to 85% in sensitivity analyses.
The average time for symptom onset between successive cases (serial interval) is 8.5 days, and the time from infection to symptom onset (incubation period) is 5.6 days, new data show.